Background: Human organic cationic transporter1 (Hoct1) is a plasma membrane transporter responsible for the main influx of Imatinib into chronic myeloid leukemia (CML) cells. Single nucleotide polymorphisms (SNPs) in the gene coding for hOCT1 are important factors causing Imatinib resistance. We investigated the frequency of hOCT1 SNP C480G among Egyptian CML patients and its relation to early molecular response as an indicator of treatment outcome. Materials and Methods: Two groups of CML patients were included in this study. Group I consisted of 25 patients responding to Imatinib treatment (Imatinib responsive) and group II consisted of 25 patients resistant to Imatinib (Imatinib resistant). Response criteria were assessed according to the NCCN (National Comprehensive Cancer Network) guidelines 2017. Twenty healthy controls of matched age and sex were also included (group III). For all patients, we studied hOCT1 C480G at initial presentation using Taqman drug metabolism genotyping as well as BCR-ABL percent at diagnosis and after 3 months interval. Results: hOCT1 C480G was present in 32% of studied CML patients. CC (wild) was detected in 68% of group I and 64% of group II. CG (mutant heterozygous) was present in 28% of group I and 36% of group II while GG (mutant homozygous) was detected in only one case in group I. CG was also detected in 15% of control subjects There was no significant difference between hOCT1 C480G polymorphism and Early Molecular Response (χ 2 = 0.089, p = 0.765). Conclusions: hOCT1 C480G polymorphism has no association with Imatinib resistance in Egyptian population. However, further studies on a larger number of patients are still How to cite this paper: Hamed, N.A.M., Neanea, H., Ghanem, A.M., Elgammal, M.M
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Introduction
CML (Chronic Myeloid Leukemia) is a myeloproliferative neoplasm with an incidence of 1 -2:100,000 people in developed nations and it is caused by a balanced translocation t(9;22) (q34;q11.2) [1] . There is slight male predominance with male to female ratio 1.6. The majority of patients (around 95%) are diagnosed in CML chronic phase (CML-CP) [2] .
Imatinib was the first Tyrosine kinase inhibitor (TKI) licensed and called as "magical bullet", when it revolutionized the treatment of CML [3] [4] . The second generation TKIs Dasatinib and Nilotinib are indicated for treating patients resistant or intolerant to first-line therapy as well as first-line treatment of CML [5] . DASISION and ENESTnd studies have shown that Dasatinib and Nilotinib are associated with higher rates of molecular response and lower risk of disease progression in intermediate and high-risk group [6] [7] . However, Imatinib has clear advantages over the 2nd generation TKIs since its side effect profile is well understood and it is cheaper [8] .
The frequency of Imatinib resistance and intolerance is estimated at 30% -40% [9] . Resistance to Imatinib may be BCR-ABL1 dependent or independent.
Among the mechanisms of BCR-ABL1 independent resistance is the aberrant expressions of drug transporters that may alter intracellular plasma drug concentration [10] .
The human Organic Cation Transporter 1 (HOCT1), encoded by the solute carrier 22 family (SLC22A1) gene, is a plasma membrane transporter protein responsible for the translocation of a broad range of drugs [11] . This gene contains 11 exons and 10 introns spanning approximately 37 kb and localized on chromosome 6q26-7. HOCT1 is primarily found in sinusoidal (basolateral) membranes of hepatocytes and, to a lesser extent, in intestinal cells [12] .
Over 1000 SNPs (Single Nucleotide polymorphisms) have been identified, of which 22 have been linked to the treatment outcome of the drugs transported by HOCT1 [13] (Figure 1 ).
Among the commonest SNPs is hOCT1 C480G (rs683369) in which nucleotide 480 C is changed to G leading to Leu160Phe replacement [14] . It has a prevalence of about 22% among Caucasians. This SNP has been found to be correlated with the risk of treatment failure in CML patients [14] [15]. This study is the first one in Egypt designed to investigate the frequency of hoct1 C480G SNP and its effect on EMR to Imatinib in Egyptian CML patients while there were other studies on hOCT1 were presented by Vine et al. and Paolo et al. [14] [16].
Materials and Methods
This study included 50 CML patients treated at the Hematology Clinic, Alexan- 
hOCT1 C480G SNP Detection
At first genomic DNA extraction was done using Thermo Scientific Gene JET Genomic DNA Purification Kit. The concentration of DNA was estimated by measuring the absorbance at 260nm (A260) using a spectrophotometer (Nanodrop ® ND-1000 spectrophotometer). DNA purity was estimated from the A260/A280 ratio. An A260/A280 ratio between 1.7 and 2.0 generally represents a high-quality DNA sample. 
Measurement of BCR-ABL1 Transcripts
Total RNA was extracted from peripheral blood mononuclear cells using RNeasy
Midi Kit (Qiagen) and was converted into cDNA using ipsogen RT kit (Qiagen).
RQ-PCR was analysed through Rotor-gene Q instrument using ipsogen BCR-ABL1 kit (Qiagen). The absolute quantities of BCR-ABL and ABL transcripts in patient specimens were determined by reference to standard curves [19] . 
Statistical Analysis
Results
Baseline characteristics including age, sex, spleen size, Sokal score and Bcr-ABL1 transcripts at 3 months are presented in Table 1 and Table 2 . The distribution of hOCT1 C480G genotypes in both CML and control groups is shown in Table 1 . In group I, 68% (17 patients) were wild homozygous CC, 28% (seven patients) were heterozygous CG and 4% (one patient) was homozygous (mutant) CG. However, in group II, 64% (16 patients) were CC and 36% (nine patients) were CG. In controls, 85% (17 patients) were CC and 15% (3 patients) were CG. There was no statistically significant difference among the three studied groups (χ 2 = 4.215, p = 0.312). (eight patients) were high risk. Sokal score was significantly higher among group II especially patients carrying the CG genotype (χ 2 = 11.954, p = 0.026).
There is no significant difference in age (p = 0. There was significant difference among hOCT1 C480G genotypes and spleen size (p = 0.001) in the CML studied groups (Table 3) .
Discussion
This study aimed at investigating the frequency of the polymorphism of Hoct1 transporter C480G and EMR. The present study couldn't find a statistically significant effect of hOCT1 polymorphism on the EMR. In accordance with our results, Takahashi et al. studied hOCT1 C480G polymorphism among other polymorphisms and their effects on Imatinib drug concentration and clinical response. They found no association between hOCT1 C480G polymorphism and molecular response [20] . Cao et al. assessed HOCT1 expression level in granulocytes using indirect immunofluorescence and flow cytometry. This study revealed that hOCT1 expression was significantly associated with Imatinib efficacy and achievement of MMR (Major molecular response) [25] . The difference and contradiction in the results may be related to the different sample sizes, population under study, different methodology used and other parameters that could affect Imatinib response (namely Imatinib drug level, Hoct1 activity and gene expression).
In the present study, Sokal score was significantly advanced in group II patients especially those with the CG genotype (p = 0.026).This results are more or less similar to Chhikara et al. who reported that patients with high OCT1 expression had significant higher Sokal scores than those with low OCT1 expression [25] .
Although the present work couldn't find a significance impact of C490G polymorphism on EMR, BCR-ABL1 transcript level at 3 months were significantly higher in group II especially those having the heterozygous form (CG). CG genotype may be associated with a higher risk evidenced in this study by the statistically more advanced Sokal score and higher BCR-ABL transcripts at 3 months.
Conclusion
From this study, it was concluded that C480G polymorphism is present in Egyp-tian CML patients. EMR was not affected by the presence of C480G polymorphism in CML patients. Spleen size and Sokal score were significantly higher in patients carrying the mutant (CG) than those with normal wild (CC). So, C480G polymorphism may be associated with higher risk. Testing these findings in a larger patient population with newly diagnosed CML is recommended.
